Brief: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy
04/08/2025 12:46
Aug 4 (Reuters) - Dyne Therapeutics Inc DYN.O: DYNE THERAPEUTICS ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DYNE-251 IN DUCHENNE MUSCULAR DYSTROPHY (DMD) DYNE THERAPEUTICS INC - DATA FROM DELIVER COHORT EXPECTED LATE 2025, BLA EARLY 2026 Source text: ID:nGNX6pJ9LM Further company coverage: DYN.O ((Reuters.Briefs@thomsonreuters.com;))